Iambic Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2026-09-09.
Iambic Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on September 9, 2026. The filing reports $65.97M sold. Its industry group is Biotechnology. It names Thomas Miller (Executive Officer, Director), Fred Manby (Executive Officer, Director), Neil Josephson (Executive Officer) (SEC Form D, September 9, 2026).
Sell to companies like Iambic Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-09-09 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Iambic Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Iambic Therapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in California, filed in September 2026, largest first.
Get an email when Iambic Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Iambic Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Iambic Therapeutics, Inc. →Get the full cited report on Iambic Therapeutics, Inc.
What the filing shows about Iambic Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Iambic Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Iambic Therapeutics, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Iambic Therapeutics, Inc. See pricing
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $65.97M, on the same scale — one filing against the whole group's total, so it sits low by construction.
By form type: D ×5 · D/A ×2.
| Form | Filed | On EDGAR |
|---|---|---|
| D | 2026-09-09 | open |
| D | 2026-04-08 | open |
| D | 2025-11-21 | open |
| D/A | 2024-06-06 | open |
| D/A | 2024-05-07 | open |
| D | 2024-04-25 | open |
| D | 2023-10-12 | open |
What the filing shows about Iambic Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Iambic Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Iambic Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The 7 most recent of 7 filings on CIK 0001997038, filed as Iambic Therapeutics, Inc.. Read from the SEC's own submissions feed for this issuer, not from a third party. Incorporated in DE. Full history on sec.gov.
Checked away from the filing. What is below does not come from the record on sec.gov.
Iambic has created a cutting-edge AI-driven platform to tackle the most challenging design problems in drug discovery and address unmet patient need.
The title and description the site itself served, answering 200, after redirecting from https://iambic.ai. Not a cached copy and not the company's directory entry — what was live when we asked.
Thomas Miller is named as Executive Officer and Director on the Form D that Iambic Therapeutics, Inc. filed with the SEC on 9 September 2026, one of 13 people that filing names.
Fred Manby is named as Executive Officer and Director on the Form D that Iambic Therapeutics, Inc. filed with the SEC on 9 September 2026, one of 13 people that filing names.
Neil Josephson is named as Executive Officer on the Form D that Iambic Therapeutics, Inc. filed with the SEC on 9 September 2026, one of 13 people that filing names.
Michael Secora is named as Executive Officer on the Form D that Iambic Therapeutics, Inc. filed with the SEC on 9 September 2026, one of 13 people that filing names.
Jishnu Bhattacharjee is named as Director on the Form D that Iambic Therapeutics, Inc. filed with the SEC on 9 September 2026, one of 13 people that filing names.
Evan Rachlin is named as Director on the Form D that Iambic Therapeutics, Inc. filed with the SEC on 9 September 2026, one of 13 people that filing names.
R. Jacob Vogelstein is named as Director on the Form D that Iambic Therapeutics, Inc. filed with the SEC on 9 September 2026, one of 13 people that filing names.
Mary Tagliaferri is named as Director on the Form D that Iambic Therapeutics, Inc. filed with the SEC on 9 September 2026, one of 13 people that filing names.
William Rastetter is named as Director on the Form D that Iambic Therapeutics, Inc. filed with the SEC on 9 September 2026, one of 13 people that filing names.
Kurt von Emster is named as Director on the Form D that Iambic Therapeutics, Inc. filed with the SEC on 9 September 2026, one of 13 people that filing names.
Shalini Sharp is named as Director on the Form D that Iambic Therapeutics, Inc. filed with the SEC on 9 September 2026, one of 13 people that filing names.
Pete Olson is named as Executive Officer on the Form D that Iambic Therapeutics, Inc. filed with the SEC on 9 September 2026, one of 13 people that filing names.
Samit Hirawat is named as Director on the Form D that Iambic Therapeutics, Inc. filed with the SEC on 9 September 2026, one of 13 people that filing names.
13 people named on the filing — 5 holding an executive role and 8 as directors only.
Named as of the 2026-09-09 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
Of the 13 names on this filing, 12 are drawn here to keep the picture readable. The People tab lists them all.
No investor is drawn from a Form D — the form states how many invested and never who.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Iambic Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Iambic Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-25 (iambic.ai).
Each opens in a new tab, filled in for Iambic Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises, week of 2026-09-07 · Biotech raises in San Diego
https://mentionfox.com/funding/iambic-therapeutics-inc-form-d-000002